Connect with us
European Gaming Congress 2024

Fintech PR

Introducing Bluefin v2 – Decentralized Trading Without Wallets






LONDON, Sept. 12, 2023 /PRNewswire/ — We are excited to announce Bluefin v2 – the next step of our decentralized, orderbook-based exchange. Bluefin v1 supports the trading of perpetual swaps and is currently powered by Arbitrum, a layer 2 blockchain leveraging the security of Ethereum. To this day, v1 has processed over $1 billion in trading volume. While we will continue to operate and maintain Bluefin v1, with v2 we aim to build a decentralized platform that can match the features and trading experience of centralized exchanges, for both professional and first-time traders. This includes supporting new features such as spot trading as well as overcoming the performance limitations and high gas fees on existing Layer 2s. Today, we look forward to sharing this next iteration of the exchange.

Key Takeaways

  • Timeline: Bluefin v2 will be released in a beta state in September followed by several features that include instant trade confirmations, sub-second finality, fully-decentralized spot markets, cross-margin, and trading without wallets. These will be rolled out over the next six months.
  • Performance: ~30ms optimistic trade confirmations, ~550ms finality, 5,400+ peak TPS
  • Eliminating Wallets: We’re working to emulate the Web2 trading experience while retaining the decentralization benefits of an on-chain trading protocol
  • Cost of Execution: The spread on Bluefin v1 is currently <0.001% and with reduced latencies and gas fees below $0.005 on v2, users will benefit from even lower trade execution costs.

Bluefin v2

We are now excited to announce Bluefin v2. Over the course of this year, we’ve rewritten our codebase and built on a new underlying technology. Bluefin v2 is built on Sui, which enables horizontally scalable performance and a wallet-less trading experience that competes with the user experience of a centralized exchange. With Bluefin v2, we introduce

  1. Optimistic trades streamed sub-second and eliminating the need for wallets.
  2. Spot trading using Sui’s on-chain orderbook, further enhancing our decentralization, transparency, and security.
  3. A new margining engine with cross-margining capabilities.
  4. An underlying layer 1 that has seen a peak throughput over 5400 TPS on mainnet and a peak throughput ranging from 10,871 TPS to 297,000 TPS while benchmarking in a series of tests


Our goal is to ensure that users experience sub-second trades, finalized on-chain, and reflected instantly on their UI. These are two key performance components of Bluefin v2: optimistic trade confirmations and on-chain finality.

With Sui’s parallel execution, the availability of the network is not constrained by other applications and users. As a result, the success rate of transactions submitted on-chain is extremely high. Building on this guarantee, we’ve redesigned the off-chain orderbook layer to start sending optimistic confirmations of trades in ~30ms back to users and ensuring eventual consistency with the on-chain smart contracts in ~480ms on average based on benchmarking in a production environment.

A hyper-performant trading experience with 30ms optimistic confirmations and sub-second on-chain finality

Eliminating Wallets While Remaining Non-Custodial

We’re working on eliminating the need for users to bring their own wallets by making on-chain interactions invisible to users. Abstracting away private key management and the need for wallets altogether, while remaining non-custodial, is a key milestone for decentralized finance.  There are three phases here: i) natively-supported social login using zkLogin, ii) easy fiat on-ramp and transfers from other exchanges and blockchains, and, iii) eliminating wallets altogether.

Bluefin to support a wallet-less trading experience while remaining non-custodial

We will be releasing v2 features on a rolling basis over the course of the next 6 months, however, an early version of the protocol will be available later this month. The current version of the exchange is live:

About Bluefin

Bluefin is an orderbook-based derivatives exchange using the most innovative decentralized infrastructure to support first-time users and professional traders. Please view our terms of use and privacy policy before accessing the platform.



Zabi Mohebzada, [email protected]

Photo –

Photo –

Photo –

Cision View original content:—decentralized-trading-without-wallets-301923813.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Fintech PR

Invitation to presentation of EQT AB’s Q1 Announcement 2024




STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.

The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.

To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.

The webcast can be followed live here and a recording will be available afterwards.

Information on EQT AB’s financial reporting


The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.

The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.

Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]

Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334

This information was brought to you by Cision


The following files are available for download:

Invitation to presentation of EQT AB’s Q1 Announcement 2024,c3285895


EQT AB Group


View original content:

Continue Reading

Fintech PR

Kia presents roadmap to lead global electrification era through EVs, HEVs and PBVs



  • Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
  • Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
  • Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
    • Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
    • PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
  • Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
  • 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
  • CEO reaffirms Kia’s commitment to ESG management

SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.

Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.

During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.

The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.

“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”


Photo –

Cision View original content to download multimedia:

Continue Reading

Fintech PR

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update




VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.

As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.

The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.

Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.

About BioVaxys Technology Corp.


BioVaxys Technology Corp. (, a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit and connect with us on X and LinkedIn.


Signed “James Passin
James Passin, Chief Executive Officer
Phone: +1 646 452 7054

Logo –

Cision View original content:

Continue Reading